Hillstream BioPharma is a pre-clinical biotech company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer mechanism resulting in iron mediated cell death (“IMCD”) for treatment-resistant cancers. Our most advanced product candidate is HSB-1216, an IMCD inducer, targeting a variety of solid tumors. In a clinical pilot study conducted in Germany by the University […]

We are an online retailer of home goods, toys, apparel and consumer electronics. We operate as a wholesaler on Amazon. We generate most of our revenue as a third-party seller on Amazon (www.amazon.com). In late 2020, the company expanded to offer goods online at Walmart (www.walmart.com). We also sell merchandise on our own website: www.hourloop.com. […]

We intend to focus on businesses that have their primary operations located in North America and Europe in the neuro-musculoskeletal industry. Our sponsor is an affiliate of Viscogliosi Brothers, LLC (“VB”), a single-family office founded by Anthony, John, and Marc Viscogliosi, with extensive experience in the neuro-musculoskeletal (“NMS”) industry. VB has invested in more than […]

We intend to focus on businesses at the leading edge of innovation in national security in these three key sectors: space, cybersecurity and energy transition. (Note: C5 Acquisition Corp. priced its SPAC IPO on Jan. 6, 2022, in line with the terms in its prospectus: 25 million units at $10 each to raise $250 million.)

We intend to focus on the media and entertainment sectors. (Blank check company incorporated in the Cayman Islands) Our management team has extensive experience with blank check companies, also known as special-purpose acquisition companies (SPACs), going back to 2011, with the following eight SPACs: Spinning Eagle, Soaring Eagle, Flying Eagle, Diamond Eagle, Platinum Eagle, Double […]

(Note: Affinia Therapeutics, Inc. withdrew its IPO plans in an SEC filing dated Dec. 2, 2022. The S-1 was filed on Jan. 4, 2022. No terms were filed, although estimated IPO proceeds were $100 million.) We are a preclinical stage company pioneering a new class of rationally designed gene therapies with potentially curative benefit in […]

We currently intend to focus our efforts on identifying high growth technology and tech-enabled businesses domestically and abroad in the consumer Internet, ecommerce, software, healthcare, transportation / mobility and financial services industries, as well as other industries that are being disrupted by advances in technology and on technology paradigms, including artificial intelligence (“AI”), automation, data […]

We intend to seek a business combination with an India-focused technology firm that will benefit from our sponsors’ extensive global investment experience. We will focus on target companies with a valuation of $1 billion or more. (Incorporated in the Cayman Islands)  Our sponsor and the Cartica Funds, which are providing the capital to our sponsor […]

Our mission is to develop therapies that change the treatment paradigm for amyotrophic lateral sclerosis, or ALS, and a broad range of neurodegenerative diseases by keeping neurons alive. Unlike most other cells in the body that regularly die and are replaced as part of healthy function, mature neurons are normally resistant to cell death and […]

We are a clinical-stage biopharmaceutical company focused on developing our lead clinical candidate, CIN-107, for the treatment of hypertension and other cardio-renal diseases. CIN-107 is a highly selective, oral small molecule inhibitor of aldosterone synthase, the enzyme responsible for the synthesis of aldosterone in the adrenal gland. CIN-107 has been designed to use a differentiated mechanism of action, direct […]